BioMed Research International

Biological Insights into Myeloma and Other B Cell Malignancies


Status
Published

1Dana-Farber Cancer Institute, Boston, USA

2Magna Graecia University of Catanzaro, Catanzaro, Italy

3University of Genoa, Genoa, Italy

4University of Navarra, Pamplona, Spain

5Washington University, Saint Louis, USA


Biological Insights into Myeloma and Other B Cell Malignancies

Description

Despite advances in multiple myeloma (MM) therapy, the majority of patients eventually die from the disease. Although various aspects of MM pathobiology are well established, there is increasing awareness that MM cell-bone marrow stromal cell (BMSC) interactions support growth and survival of the tumor cells and lead to the development of drug resistance. Nonetheless, MM cells accumulate various genetic and epigenetic abnormalities that drive the malignant phenotype and confer distinct biologic sequelae and disease outcomes. This has prompted continued search to understand molecular changes in MM and potential ways to target them.

This special issue will focus on the current understanding of MM biology with emphasis on identification and validation of new targets and pathways for prognostic and therapeutic application.

We invite authors to contribute original research articles as well as review articles.

Potential topics include, but are not limited to:

  • Therapeutic relevance of novel targets regulating tumor cell growth, survival, and drug resistance in vitro and in vivo
  • Development of drug combinations
  • Myeloma bone disease
  • Transcriptional regulation in myeloma and other B cell malignancies
  • Role of epigenetics in the biology of multiple myeloma
  • MicroRNA as potential target for gene therapy
  • Genome instability in MM disease progression and prognosis
  • Immunomodulation in myeloma

Articles

  • Special Issue
  • - Volume 2016
  • - Article ID 5218093
  • - Editorial

Biological Insights into Myeloma and Other B Cell Malignancies

Mariateresa Fulciniti | Nicola Amodio | ... | Abdel Kareem Azab
  • Special Issue
  • - Volume 2016
  • - Article ID 7870590
  • - Research Article

Plasma Levels of Monocyte Chemotactic Protein-1 Are Associated with Clinical Features and Angiogenesis in Patients with Multiple Myeloma

Toni Valković | Emina Babarović | ... | Nives Jonjić
  • Special Issue
  • - Volume 2016
  • - Article ID 6504593
  • - Review Article

MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment

Lavinia Raimondi | Angela De Luca | ... | Nicola Amodio
  • Special Issue
  • - Volume 2015
  • - Article ID 165238
  • - Review Article

ZNF423 and ZNF521: EBF1 Antagonists of Potential Relevance in B-Lymphoid Malignancies

Maria Mesuraca | Emanuela Chiarella | ... | Giovanni Morrone
  • Special Issue
  • - Volume 2015
  • - Article ID 832049
  • - Review Article

Deep Response in Multiple Myeloma: A Critical Review

Mariateresa Fulciniti | Nikhil C. Munshi | Joaquin Martinez-Lopez
  • Special Issue
  • - Volume 2015
  • - Article ID 341430
  • - Review Article

Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma

Wen-Chi Yang | Sheng-Fung Lin
  • Special Issue
  • - Volume 2015
  • - Article ID 856704
  • - Research Article

The Applicability of the International Staging System in Chinese Patients with Multiple Myeloma Receiving Bortezomib or Thalidomide-Based Regimens as Induction Therapy: A Multicenter Analysis

Jing Lu | Jin Lu | ... | Jian Hou
  • Special Issue
  • - Volume 2015
  • - Article ID 943096
  • - Review Article

Mechanisms and Clinical Applications of Genome Instability in Multiple Myeloma

Antonia Cagnetta | Davide Lovera | ... | Michele Cea
  • Special Issue
  • - Volume 2015
  • - Article ID 172458
  • - Review Article

Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling

Fabrizio Accardi | Denise Toscani | ... | Nicola Giuliani
  • Special Issue
  • - Volume 2015
  • - Article ID 417586
  • - Research Article

Inhibition of P-Selectin and PSGL-1 Using Humanized Monoclonal Antibodies Increases the Sensitivity of Multiple Myeloma Cells to Bortezomib

Barbara Muz | Feda Azab | ... | Abdel Kareem Azab
BioMed Research International
 Journal metrics
Acceptance rate31%
Submission to final decision67 days
Acceptance to publication30 days
CiteScore3.600
Impact Factor2.276
 Submit